Scientific article

Pharmacogenetics-based population pharmacokinetic analysis of etravirine in HIV-1 infected individuals

Published inPharmacogenetics and genomics, vol. 23, no. 1, p. 9-18
Publication date2013

Etravirine (ETV) is metabolized by cytochrome P450 (CYP) 3A, 2C9, and 2C19. Metabolites are glucuronidated by uridine diphosphate glucuronosyltransferases (UGT). To identify the potential impact of genetic and non-genetic factors involved in ETV metabolism, we carried out a two-step pharmacogenetics-based population pharmacokinetic study in HIV-1 infected individuals.

  • Adolescent
  • Adult
  • Aged
  • Aryl Hydrocarbon Hydroxylases/genetics
  • Cytochrome P-450 CYP3A/genetics
  • Female
  • HIV Infections/drug therapy/epidemiology/genetics
  • HIV Protease Inhibitors/pharmacokinetics/pharmacology
  • HIV-1/drug effects/genetics
  • Humans
  • Male
  • Middle Aged
  • Models
  • Statistical
  • Pharmacogenetics
  • Polymorphism
  • Single Nucleotide/genetics
  • Prognosis
  • Prospective Studies
  • Pyridazines/pharmacokinetics/pharmacology
  • Switzerland/epidemiology
  • Tissue Distribution
  • Young Adult
Research group
Citation (ISO format)
LUBOMIROV, Rubin et al. Pharmacogenetics-based population pharmacokinetic analysis of etravirine in HIV-1 infected individuals. In: Pharmacogenetics and genomics, 2013, vol. 23, n° 1, p. 9–18. doi: 10.1097/FPC.0b013e32835ade82
Main files (1)
Article (Published version)
ISSN of the journal1744-6872

Technical informations

Creation12/03/2013 11:42:00 AM
First validation12/03/2013 11:42:00 AM
Update time03/14/2023 8:43:21 PM
Status update03/14/2023 8:43:21 PM
Last indexation01/16/2024 8:31:13 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack